Tuebingen, Germany

Florian Koehler

USPTO Granted Patents = 7 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Mind of Florian Koehler: Pioneering Immunotherapy Solutions

Introduction: Florian Koehler, an accomplished inventor based in Tuebingen, Germany, has made remarkable contributions to the field of biotechnology. With a total of seven patents to his name, Koehler is recognized for his significant advancements in immunotherapy, particularly in the fight against various types of cancers.

Latest Patents: Among his notable inventions is a groundbreaking peptide designed for use in immunotherapy against different types of cancers. This invention pertains to a peptide comprising an amino acid sequence selected from a specific group, including SEQ ID NO: 1 to SEQ ID NO: 216, as well as variant sequences that maintain the capacity to bind to MHC molecules and induce T cells to cross-react with the variant peptide, or pharmaceutically acceptable salts thereof.

Career Highlights: Koehler's innovative work is supported by his association with Immatics Biotechnologies GmbH, a company at the forefront of cancer immunotherapy solutions. His research and inventions are crucial in developing therapies that aim to enhance the immune response against tumor cells, showcasing the potential of targeted immunotherapeutic approaches.

Collaborations: Throughout his career, Florian Koehler has collaborated with esteemed colleagues such as Ricarda Hannen and Jens Hukelmann. These partnerships underline the importance of teamwork in driving innovation and fostering an environment conducive to groundbreaking research and development in the biotechnology sector.

Conclusion: Florian Koehler stands as a pivotal figure in the field of immunotherapy, leveraging his expertise to create innovative solutions for cancer treatment. His patents not only demonstrate his inventive capabilities but also contribute significantly to advancing medical science and improving patient outcomes globally.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…